Perlmutter Cancer Center Taps Vivek Subbiah, MD, to Lead Early-Phase Drug Development and Rare Cancer Programs
The physician-scientist helped advance landmark tumor-agnostic therapies that target cancer's genetic drivers. NEW YORK, Oct. 22, 2026 /PRNewswire/ -- NYU Langone Health today announced the appointment of Vivek Subbiah, MD, as director of the Early-Phase Drug Development Program and the...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.